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Human neuroblastoma cells were cultured either in the absence or presence of 12-O-tetradecanoylphorbol-13-acetate (TPA) known to induce neu- 
ronal differentiation. This treatment led to a marked increase in the concentration of secretogranin II but to a decrease of chromogranin A. Analo- 
gous changes were observed for the respective mRNAs. Thus during differentiation of these cells the biosynthesis of two vesicle constituents of 
large dense core vesicles is differentially regulated as determined both at the mRNA and the protein level. Levels of both synaptin/synaptophysin 
and SV2 were also elevated but to a smaller degree than that of secretogranin II. 
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1. INTRODUCTION 
The catecholamine-storing organelles of the adrenal 
medulla, the chromaffin granules, and the large dense 
core vesicles of sympathetic nerve contain a complex 
‘secretory cocktail’ [ 11. Apart from the hormones these 
vesicles comprise neuropeptides and the so-called 
chromogranins [2,3]. Previous studies have already 
established that the biosynthesis of these components is 
not regulated en bloc allowing a significant blending of 
the secretory cocktail (adrenal medulla [4,5]; PClZcells 
[6]; see also [7]). 
In the present study the levels of various components 
of secretory vesicles and their mRNAs were studied in 
human neuroblastoma cells (SH-SYSY). These cells dif- 
ferentiate morphologically, biochemically, and func- 
tionally, and are growth inhibited when treated with 
nanomolar concentrations of 12-O-tetradecanoylphor- 
bol-13-acetate (TPA) [8-111. Notably, the noradrenali- 
ne concentration increases 2OO-300-fold, dense core 
granules become more frequent, and the resting mem- 
brane potential increases [&lo]. Furthermore, the SH- 
SYSY cells express muscarinic acetylcholine receptors 
[l 1,121, and when the TPA-treated cells are exposed to 
acetylcholine, the stored noradrenaline is released via a 
Ca2+ -dependent process [l 11. In the present paper we 
demonstrate that TPA treatment of these cells 
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downregulates the biosynthesis of chromogranin A 
whereas that of secretogranin II (chromogranin C; for 
nomenclature see [13]) is markedly elevated. Levels of 
SV2 [ 141 and synaptin/synaptophysin [15] are 
moderately increased. 
2. MATERIAL AND METHODS 
2.1. Cell culture 
The SH-SYSY cells 1161, kindly provided by June Biedler (Sloan 
Kettering Institute for Cancer Research, New York, NY), were 
cultured and differentiated by 16 nM TPA as described [9]. Essential- 
ly, lo6 cells were seeded per 8.5 cm dish with or without differentia- 
tion inducer, and the cells were harvested at the indicated time points. 
Once the cells were harvested, they were stored at - 70°C as a pellet, 
until they were lyophilized and analysed. 
2.2. Itnmunoblotting 
The harvested cells were subjected to quantitative immunoblotting 
as already described in detail 1171. The following rabbit antisera were 
used: anti-human chromogranin A, anti-rat secretogranin II [18], 
anti-synaptin/synaptophysin (kindly provided by R. Jahn, Munich). 
For SV2 a monoclonal antibody, 10 H3 [14], was employed. Protein 
was determined according to Lowry [19]. 
2.3. RNA-extraction 
Cells were cultured in 6 well dishes for 5 days at a density of 
2 x 10’ per well. RNA was extracted with a guanidinium thiocyanate 
method [20]. Total RNA from two wells was combined, size- 
fractionated on denaturing agarose gels transferred electrophoretical- 
ly to nylon membranes and hybridized for chromogranin A with a 
57-mer oligonucleotide against human chromogranin A (bases 
224-280) [21] labelled with T4 polynucleotide kinase. For 
secretogranin II a 756 bp BgnI fragment of an adrenal medullary 
bovine secretogranin II clone [22] labelled by random priming was 
used. 
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Fig. 1. Levels of constituents of storage vesicles in human 
neuroblastoma cells. Cells were cultured for up to 12 days in the 
absence or presence of 16 nM TPA (T) and were then analysed by 
quantitative immunoblotting. The results are expressed per mg 
protein as percentages of the levels in controls at day 4 which were 
taken as 100%. Mean values (several determinations for 3 different 
cultures) f SE are shown (n = 9 for Ch A; n = 10 for Sg II; n = 12-13 
for SYN: n = 10 for SV2). The differences between controls and TPA- 
treated cultures were statistically significant for all components and at 
each time point (P< 0.05 to PC 0.001). Ch A, chromogranin A; Sg II, 
secretogranin II (chromogranin C); SYN, synaptin/synaptophysin. 
ChA SgH 
C TCT 
Fig. 2. Northern blots for the mRNA of chromogranin A and 
secretogranin II. Total RNA was extracted from control (C) and TPA 
(T)-treated cultures (after 5 days). The blots were either hybridized 
with chromogranin A (Ch A) or secretogranin II (Sg II) probes. The 
positions of the 28 S and 18 S ribosomal RNAs are indicated at the left 
side of the figure. 
3. RESULTS 
Several constituents of sympathetic large dense core 
vesicles and synaptic vesicles were determined in human 
neuroblastoma cell cultures in the absence or presence 
of TPA. Fig. 1 compiles the results. In control cultures 
over 12 days the levels of secretogranin II, synap- 
tin/synaptophysin and SV2 did not change significantly 
whereas that of chromogranin A reached a higher level 
after 8 days. TPA treatment induced significant 
changes. A marked increase was observed for 
secretogranin II already after 4 days. At 8 days the level 
was even higher and then declined, which in part might 
be due to an increase in the population of non- 
responding cells [9]. On the other hand, chromogranin 
A levels were reduced when compared to controls. For 
the two membrane components, SV2 and synap- 
tin/synaptophysin, increased levels from days 4 to 12 
were observed. 
Fig. 2 demonstrates the changes in the levels of the 
mRNAs for chromogranin A and secretogranin II in- 
duced by TPA. The chromogranin A message was 
significantly reduced by this agent (38.7 + 4.2%, SE, 
of controls; n = 6, P< 0.001). On the other hand the 
secretogranin II message was markedly increased 
(1001.6 x 129.0%, SE, n=6, P<O.OOl). 
4. DISCUSSION 
The subcellular localization of the 4 components 
measured in this study is not identical. Chromogranin 
A and secretogranin II are constituents of chromaffin 
granules [2] and of large dense core vesicles in nerve 
[23]. SV2 and synaptin/synaptophysin are also present 
in these organelles [24-261 but are also found in translu- 
cent synaptic vesicles in apparently higher concentra- 
tion [27]. Let us first discuss the differential changes in 
the biosynthesis of chromogranin A/secretogranin II 
which are relevant for the secretory content of large 
dense core vesicles. Previous studies have established 
that TPA treatment of human neuroblastoma cells 
leads to a differentiation which is accompanied by pro- 
found changes, including axonal growth and increased 
expression of the GAP43 gene coding for the axonal 
growth-area associated protein 43 [8-l 1,281. In 
analogy, IMR-32 human neuroblastoma cells acquire 
regulated secretory properties after drug-induced dif- 
ferentiation [29]. These differentiated cells contain 
typical secretory granules comprising chromogranins/ 
secretogranin [29]. We have now demonstrated that dif- 
ferentiation does not simply turn on the biosynthesis of 
chromogranin Aisecretogranin II together. Quite to the 
contrary, a marked increase of secretogranin II is 
paralleled by a fall of chromogranin A and these 
changes are apparently based on a different regulation 
of their respective mRNAs. Previous studies have 
established that chromogranin A, B and secretogranin 
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II are not always regulated together. Thus, only the 
biosynthesis of chromogranin A depends on cor- 
ticosteroids [4-61. The present result provides a further 
clear-cut example of a differential regulation of these 
peptides costored within the same organelle [30]. An 
analogous behaviour to secretogranin II has recently 
been found for another protein apparently stored in 
large dense core vesicles of PC12 cells [31]. 
Our results suggest hat TPA-induced differentiation 
of sympathetic ells to a more neuronal phenotype is ac- 
companied by an increase in the biosynthesis of 
secretogranin II and by a decrease of chromogranin A. 
Previously we have already shown that large dense core 
vesicles of bovine sympathetic nerve when compared to 
adrenal chromaffin granules have a relatively higher 
content of secretogranin II versus the other chro- 
mogranins [23] and the same applies to brain tissue of 
the rat [32]. These data are consistent with a concept 
that the levels of secretogranin II are increased during 
differentiation of sympathetic ells to neurons. 
The changes in the levels of two membrane com- 
ponents are more difficult to interpret. Their concomi- 
tant increase is smaller than that of the secretory protein 
secretogranin II. Does this indicate that more large 
dense core vesicles are formed and in addition, that 
each vesicle is filled with more soluble protein? On the 
other hand, the largest portion of these membrane com- 
ponents may be present in small translucent vesicles 
[26,27] and an increase might be due to more vesicles of 
this type. In any case we have established that the syn- 
thesis of these two membrane components is apparently 
not regulated separately during differentiation and 
compared with secretogranin II the increase in their 
synthesis is much smaller. This makes the TPA effect 
on secretogranin II expression even more specific and 
relevant. 
Acknowledgements: This paper was supported by the Fonds zur 
Forderung der wissenschaftlichen Forschung (Austria) and by the Dr 
Legerlotz-Stiftung (H.W.), The Swedisch Cancer Society (S.P.), The 
Children Cancer Foundation of Sweden (S.P.), HKH Kronprinsessan 
Lovisas Forening for Barnasjukvard, Hans von Kantzows and Ollie 
och Elof Ericssons Stiftelser (S.P.). 
REFERENCES 
[l] Winkler, H., Apps, D.K. and Fischer-Colbrie, R. (1986) 
Neuroscience 18, 261-290. 
[2] Fischer-Colbrie, R., Hagn, C. and Schrober, M. (1987) Ann. NY 
Acad. Sci. 493, 120-134 
[3] Simon, J.-P. and Aunis, D. (1989) Biochem. J. 262, 1-13. 
[4] Sietzen, M., Schober, M., Fischer-Colbrie, R., Scherman, D., 
Sperk, G. and Winkler, H. (1987) Neuroscience 22, 131-139. 
[5] Fischer-Colbrie, R., Iacangelo, A. and Eiden, L.E. (1988) Proc. 
Natl. Acad. Sci. USA 85, 3240-3244. 
[6] Rausch, D.M., Iacangelo, A. and Eiden, L.E. (1988) Mol. 
Endocrinol. 2, 921-927. 
[7] Eiden, L.E. (1987) Cell. Mol. Neurobiol. 7, 339. 
[8] Pahlman, S., Odelstad, L., Larsson, E., Grotte, G. and Nilsson, 
K. (1981) Int. J. Cancer 28, 583-589. 
[9] Pahlman, S., Ruusala, A.-I., Abrahamsson, L., Odelstad, L. 
and Nilsson, K. (1983) Cell Diff. 12, 165-170. 
[lo] Akerman, K.E.O., Scott, I.G. and Andersson, L.C. (1984) 
Neurochem. Int. 6, 77-80. 
[ll] Scott, I.G., Akerman, K.E.O., Heikkila, J.E., Kaila, K. and 
Andersson, L.C. (1986) J. Cell Physiol. 126, 285-292. 
[12] Adem, A., Mattsson, M.E.K., Nordberg, A. and Pahlman, S. 
(1987) Dev. Brain Res. 33, 235-242. 
[13] Eiden, L.E., Huttner, W.B., Mallet, J., O’Connor, D.T., 
Winkler, H. and Zanini, A. (1987) Neuroscience 21, 1019-1021. 
[14] Buckley, K. and Kelly, R.B. (1985) J. Cell Biol. 100, 1284-1294. 
[15] Gaardsvoll, H., Obendorf, D., Winkler, H. and Bock, E. (1988) 
FEBS Lett. 242, 117-120. 
[16] Biedler, J.L., Roffler-Tarlov, S., Schachner, M. and Freedman, 
L.S. (1978) Cancer Res. 38, 3751-3757. 
[17] Schober, M., Howe, P.R.C., Sperk, G., Fischer-Colbrie. R. and 
Winkler, H. (1989) Hypertension 13, 469-474. 
[18] Fischer-Colbrie, R. and Schober, M. (1987) J. Neurochem. 48, 
262-270. 
[19] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. 
(1951) J. Biol. Chem. 193, 265-275. 
[20] Chomczynski, P. and Sacchi, N. (1987) Anal. Biochem. 162, 
156-159. 
[21] Konecki, D.S., Benedum, U.M., Gerdes, H.H. and Huttner, 
W.B. (1987) J. Biol. Chem. 262, 17026-17030. 
[22] Fischer-Colbrie, R., Gutierrez, J. Hsu, C.-M., Iacangelo, A. 
and Eiden, L.E. (1990) J. Biol. Chem. in press. 
[23] Hagn, C., Klein, R.L., Fischer-Colbrie, R., Douglas II, B.H. 
and Winkler, H. (1986) Neurosci. Lett. 67, 295-300. 
[24] Bock, E. and Helle, K.B. (1977) FEBS Lett. 82, 175-178. 
[25] Lowe, A.W., Maddedu, L. and Kelly, R.B. (1988) J. Cell Biol. 
106, 51-59. 
[26] Obendorf, D., Schwarzenbrunner, U., Fischer-Colbrie, R., 
Laslop, A. and Winkler, H. (1988) J. Neurochem. 51, 
1573-1580. 
[27] De Camilli, P. and Jahn, R. (1990) Annu. Rev. Physiol. 52, in 
press. 
[28] Bjelfman, C., Meyerson, G., Cartwright, C.A., Mellstrom, K., 
Hammerling, U. and Pahlman, S. (1990) Mol. Cell Biol. 10, 
361-370. 
[29] Sher, E., Denis-Donini, S., Zanini, A., Bisiani, C. and 
Clementi, F. (1989) J. Cell Biol. 108, 2291-2300. 
[30] Steiner, H.-J., Schmid, K.W., Fischer-Colbrie, R., Sperk, G. 
and Winkler, H. (1989) Histochemistry 91, 473-477. 
[31] Possenti, R., Eldridge, J.D., Paterson, B.M., Grasso, A. and 
Levi, A. (1989) EMBO J. 8, 2217-2223. 
[32] Weiler, R., Wohlfarter, T., Marksteiner, J., Schmid, K.W., 
Sperk, G. and Winkler, H. (1989) J. Neurochem. 52, S84A. 
29 
